BioSpace News Archive

Imsidolimab treatment did not demonstrate statistically significant improvement over placebo in PPPASI change from baseline at week 16 primary endpoint Imsidolimab was generally well tolerated and no serious or severe adverse events were reported in the drug arm of the trial AnaptysBio does not currently plan to conduct further clinical development in PPP Advancement of imsidolimab to continue across 5 other distinct indications, including anticipated advancement into Phase 3 trial in general

Alteogen Inc. (KOSDAQ:196170) announced that it has completed Phase 1 clinical trial of Eylea® Biosimilar (ALT-L9). The clinical trial was conducted at 4 major hospitals in Korea:

Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2020.

IQVIA™ (NYSE: IQV) announces that since September 2020 it has been collaborating with Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, on the Phase 3 COVID-19 vaccine clinical trials. The studies leverage IQVIA’s suite of decentralized trial solutions that support both on-site and remote study delivery through a mix of tel

Zomedica Corp., a veterinary health company creating point-of-care diagnostics products for dogs and cats, announced that it has effected the exchange of all of its outstanding Series 1 Preferred Shares for its common shares and that it continues to progress with its planned commercialization of its TRUFORMA® platform.

Improved reimbursement from expanded implementation of 3D mammography and increases in capitation contracts and cash collections drove increased Revenue

BWXT Medical Ltd. and Global Medical Solutions, Ltd. have entered into a joint venture to manufacture and distribute radioisotopes and radiopharmaceuticals in the Asia-Pacific.

VBL Therapeutics (Nasdaq: VBLT) today announced the Company will participate in the following upcoming virtual investor conferences: H.C Wainwright Global Life Sciences Conference Tuesday, March 9, 2021 Presentation available on-demand beginning at 7:00 a.m. ET 33rd Annual Roth Conference

Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases, today announced it will present data from two of its clinical development programs for NASH at the NASH-TAG Conference 2021, taking place March 11-13, 2021

Viatris Inc. (NASDAQ: VTRS) and Kindeva Drug Delivery L.P. today announced that the U.S. Food and Drug Administration (FDA) granted tentative approval of budesonide